

### Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

### Listing of Claims

1. (Currently Amended) A method for ~~depleting double negative T-cells~~ treating or preventing an autoimmune disease, a lymphoproliferative disease, or an allergy in a subject, said method comprising:
  - (a) identifying a subject as having, or at risk of having, an autoimmune disease, a lymphoproliferative disease, or an allergy; and
  - (b) administering to said subject an effective amount of ~~a 4-1BB-agonist~~ an antibody that binds to 4-1BB and wherein said administration results in depletion of double negative decreases the number of CD4<sup>+</sup> T cells and increases the number of CD8<sup>+</sup> T cells in said subject.
2. (Original) The method of claim 1, wherein said subject is a human.
3. (Currently Amended) The method of claim 1, ~~further comprising depleting wherein~~ administration of said antibody results in depletion of autoreactive B cells in said subject, ~~wherein said 4-1BB-agonist is effective to deplete said autoreactive B-cells.~~
4. (Cancelled)
5. (Currently Amended) The method of claim ~~[[4]]~~ 1, wherein said antibody is a monoclonal antibody.
6. (Cancelled)
7. (Previously Presented) The method of claim 1, further comprising administering interferon- $\gamma$  to said subject.

8. (Previously Presented) The method of claim 1, further comprising administering a Gr-1-binding agent to said subject, wherein said Gr-1 binding agent is an antibody that binds to Gr-1.
9. (Cancelled)
10. (Original) The method of claim 1, wherein said autoimmune disease or said lymphoproliferative disease is systemic lupus erythematosus.
11. (Withdrawn) The method of claim 1, wherein said autoimmune disease is insulin-dependent diabetes mellitus.
12. (Withdrawn) The method of claim 1, wherein said autoimmune disease or said lymphoproliferative disease is selected from the group consisting of an inflammatory bowel disease, a celiac disease, an autoimmune thyroid disease, Sjogren's Syndrome, autoimmune gastritis, pernicious anemia, autoimmune hepatitis, cutaneous autoimmune diseases, autoimmune dilated cardiomyopathy, myocarditis, myasthenia gravis, vasculitis, autoimmune diseases of the muscle, autoimmune diseases of the testis, autoimmune diseases of the ovary, and autoimmune diseases of the eye.
13. (Withdrawn) The method of claim 1, wherein said allergy is to pollen antigens, fungal antigens, insect antigens, bacterial antigens, mammalian antigens, or insect venom antigens.
- 14-16. (Cancelled)
17. (Original) The method of claim 1, further comprising:
  - (c) monitoring said subject for symptoms of said autoimmune disease, lymphoproliferative disease, or allergy.
18. (Currently Amended) A method for ~~inducing death of a double negative T cell~~ decreasing the number of CD4<sup>+</sup> T cells and increasing the number of CD8<sup>+</sup> T cells in a subject, said

method comprising contacting said double negative T cell with administering to said subject an effective amount of a 4-1BB agonist an antibody that binds to 4-1BB and wherein said contacting results in death of said double negative T cell decreases the number of CD4<sup>+</sup> T cells and increases the number of CD8<sup>+</sup> T cells.

19. (Cancelled)
20. (Currently Amended) The method of claim [[19]] 18, wherein said antibody is a monoclonal antibody.
- 21-22. (Cancelled)
23. (Currently Amended) The method of claim 18, further comprising inducing wherein administration of said antibody results in death of an autoreactive B cell cells in said subject, wherein said autoreactive B cell is contacted with said effective amount of said 4-1BB agonist.
- 24-25. (Cancelled)
26. (Currently Amended) The method of claim [[25]] 18, wherein said subject is a human.
27. (Original) The method of claim 25, wherein said subject has or is at risk for having an autoimmune disease, a lymphoproliferative disease, or an allergy.
28. (Original) The method of claim 27, wherein said autoimmune disease or said lymphoproliferative disease is systemic lupus erythematosus.
29. (Withdrawn) The method of claim 27, wherein said autoimmune disease is insulin-dependent diabetes mellitus.
30. (Withdrawn) The method of claim 27, wherein said autoimmune disease or said lymphoproliferative disease is selected from the group consisting of an inflammatory bowel disease, a celiac disease, an autoimmune thyroid disease, Sjogren's Syndrome, autoimmune gastritis, pernicious anemia, autoimmune hepatitis, cutaneous autoimmune

diseases, autoimmune dilated cardiomyopathy, myocarditis, myasthenia gravis, vasculitis, autoimmune diseases of the muscle, autoimmune diseases of the testis, autoimmune diseases of the ovary, and autoimmune diseases of the eye.

31. (Withdrawn) The method of claim 27, wherein said allergy is to pollen antigens, fungal antigens, insect antigens, bacterial allergens, mammalian antigens, or insect venom antigens.
- 32-34. (Cancelled)